Exploring how nutrition, insulin signaling, energy availability, endocrine regulation, and metabolic health influence menstrual function, fertility, pregnancy, and menopause—and why women's healthcare requires a more integrated approach.
What if reproductive health is not determined by the ovaries alone?
When women experience irregular menstrual cycles, difficulty conceiving, hormonal changes, or symptoms associated with menopause, attention often focuses primarily on reproductive hormones.
Estrogen, progesterone, follicle-stimulating hormone, and luteinizing hormone are important regulators of reproductive physiology.
However, these hormones do not function independently.
Their activity is influenced by signals arising from the brain, liver, pancreas, adipose tissue, gastrointestinal system, and broader metabolic environment.
The body continuously integrates information about energy availability, nutrient status, glucose regulation, and physiological demands.
These signals help determine how resources are distributed among essential processes, including reproduction.
Consequently, reproductive dysfunction may sometimes reflect disturbances involving systems outside the reproductive organs.
The reverse is also true.
Changes in ovarian hormone signaling can influence metabolic function, including insulin sensitivity, fat distribution, and cardiovascular risk.
This complex relationship is the subject of an October 2026 review published in Nature Metabolism, titled Metabolic Homeostasis and Women's Reproductive Health, by Liu and colleagues.
The researchers synthesized evidence describing how reproductive and metabolic organs participate in an interconnected network of hormonal and molecular communication.
Their review examined conditions ranging from polycystic ovary syndrome and endometriosis to pregnancy complications and reproductive aging.
It also explored how nutrition, exercise, medications, and other metabolism-focused interventions might influence reproductive outcomes.
The findings reinforce an important development in women's healthcare:
Reproductive health is not simply a function of ovarian hormones. It emerges through continuous interactions between the reproductive system and the metabolic systems that support it.
Understanding these relationships offers a more comprehensive foundation for prevention, assessment, and personalized care throughout a woman's life.
1. What Is Metabolic Homeostasis?
Metabolic homeostasis describes the processes through which the body regulates energy production, nutrient availability, storage, and utilization.
These processes involve several organs working together.
The pancreas releases insulin and other hormones involved in glucose regulation.
The liver helps coordinate glucose availability, lipid metabolism, and the processing of circulating substances.
Skeletal muscle contributes substantially to glucose disposal and energy expenditure.
Adipose tissue stores energy and releases signaling molecules.
The gastrointestinal system absorbs nutrients and produces hormones involved in appetite and metabolic regulation.
The nervous system integrates information from these tissues and helps coordinate appropriate physiological responses.
Importantly, metabolic homeostasis is dynamic.
The body does not maintain identical metabolic conditions during sleep, exercise, fasting, pregnancy, or recovery.
Instead, it adjusts according to changing demands.
Reproduction is among the physiological processes influenced by these adjustments.
Ovulation, pregnancy, and lactation require coordinated endocrine activity and appropriate nutritional resources.
When the body's metabolic environment changes, reproductive regulation may change as well.
2. The Hypothalamic–Pituitary–Ovarian Axis: The Brain's Role in Reproduction
Female reproductive function is coordinated through the hypothalamic–pituitary–ovarian axis, commonly abbreviated as the HPO axis.
The hypothalamus releases gonadotropin-releasing hormone, or GnRH, in a pulsatile pattern.
These signals stimulate the pituitary gland to release follicle-stimulating hormone and luteinizing hormone.
FSH and LH then act on the ovaries to regulate follicular development, ovulation, and reproductive hormone production.
Estradiol and progesterone participate in feedback signaling to the hypothalamus and pituitary.
These interactions generate the changing hormonal patterns characteristic of the menstrual cycle.
However, the HPO axis does not operate independently of the rest of the body.
It responds to information concerning energy availability, metabolic status, and other physiological conditions.
The 2026 Nature Metabolism review emphasizes that reproductive hormone regulation is integrated with several metabolic signaling pathways.
One particularly important mechanism involves a group of hypothalamic neurons that produce kisspeptin.
3. Kisspeptin: Connecting Energy Availability With Reproductive Function
Kisspeptin is a neuropeptide involved in regulating GnRH secretion.
It plays an important role in puberty, reproductive hormone signaling, and ovulation.
Kisspeptin-producing neural circuits help integrate hormonal feedback with other physiological information.
The 2026 review describes how kisspeptin signaling can respond to metabolic signals, including leptin, adiponectin, and insulin.
These interactions provide a potential mechanism through which the reproductive system responds to the body's energetic state.
For example, when energy availability becomes insufficient, reproductive hormone signaling may change.
In contrast, disturbances involving insulin resistance and other metabolic pathways may contribute to abnormal reproductive regulation in certain conditions.
Researchers are also investigating whether kisspeptin influences glucose-stimulated insulin secretion and other metabolic processes.
However, many details remain under investigation.
The presence of a biological mechanism does not establish that manipulating kisspeptin through supplements or lifestyle interventions will reliably improve fertility.
The more established clinical implication is that adequate energy availability and metabolic health contribute to normal reproductive regulation.
4. Adipose Tissue: An Endocrine Organ Involved in Fertility
Body fat is commonly described as stored energy.
However, adipose tissue performs several additional functions.
It produces signaling molecules called adipokines and participates in endocrine and immune regulation.
Two particularly important adipokines are leptin and adiponectin.
Leptin: Communicating Energy Availability
Leptin is produced primarily by adipose tissue. Its circulating concentration generally reflects the body's energy stores, although the relationship is influenced by other physiological factors.
Leptin provides information to the nervous system concerning energy sufficiency. When energy availability becomes severely restricted, leptin concentrations can decline.
Low leptin signaling may contribute to suppression of reproductive hormone activity.
This is one mechanism linking undernutrition or excessive energy deficits with menstrual dysfunction. However, higher leptin concentrations are not necessarily better.
In obesity and certain metabolic conditions, chronically elevated leptin can coexist with reduced responsiveness to its signaling. The 2026 review describes potential relationships between altered leptin signaling, ovarian function, and reproductive dysfunction.
Adiponectin: Connecting Adipose Tissue With Insulin Sensitivity
Adiponectin participates in metabolic regulation and is associated with insulin sensitivity.
Its receptors are expressed in several tissues, including metabolically and reproductively relevant organs.
The review discusses experimental evidence suggesting that adiponectin may influence ovarian steroid production and hypothalamic reproductive signaling.
However, the clinical usefulness of adiponectin measurements for reproductive decision-making remains incompletely established.
These findings illustrate why adipose tissue should be understood as a functional endocrine organ rather than merely a passive storage compartment.
5. The Liver: An Often-Overlooked Participant in Hormonal Health
The liver plays a central role in nutrient metabolism and hormone regulation.
It contributes to the synthesis, transport, and metabolism of numerous circulating substances.
One particularly relevant protein is sex hormone-binding globulin, commonly abbreviated as SHBG.
SHBG binds sex hormones, including testosterone and estradiol, and influences their circulating availability.
The liver produces most circulating SHBG.
Its production is influenced by hormonal and metabolic conditions.
The uploaded review describes how insulin resistance and increased hepatic lipid synthesis can be associated with reduced SHBG production.
Lower SHBG may increase the proportion of circulating testosterone that is unbound or loosely bound.
In certain clinical contexts, this contributes to manifestations of androgen excess.
These may include acne, excess facial or body hair, or disturbances in ovulatory function.
However, low SHBG is not a diagnosis.
Its significance depends on the individual's clinical presentation, medications, thyroid status, sex hormone concentrations, and other factors.
The liver also participates in estrogen metabolism and produces other metabolic signaling molecules.
This makes liver health relevant to broader endocrine regulation, although liver function should not be reduced to simplistic concepts of hormone detoxification.
6. Insulin: A Metabolic Hormone With Reproductive Effects
Insulin is best known for its role in blood glucose regulation.
However, it also influences other physiological processes, including aspects of ovarian hormone production.
Within the ovaries, insulin can interact with gonadotropin signaling and contribute to steroid hormone synthesis.
Under normal conditions, these interactions form part of coordinated metabolic and reproductive regulation.
However, persistent hyperinsulinemia associated with insulin resistance may influence ovarian androgen production.
The 2026 review describes how elevated insulin signaling may interact with luteinizing hormone and other pathways to increase androgen synthesis.
Insulin resistance may also affect hepatic SHBG production.
Together, these changes can contribute to certain reproductive and metabolic abnormalities.
Importantly, not every woman with irregular menstrual cycles has insulin resistance.
Likewise, not every woman with insulin resistance develops reproductive dysfunction.
The relationship must be interpreted according to the individual's clinical characteristics.
7. Why PCOS Is Being Reframed as a Metabolic and Endocrine Condition
One of the most important developments discussed in the 2026 review concerns the condition traditionally called polycystic ovary syndrome, or PCOS.
In May 2026, an international consensus proposed renaming the condition polyendocrine metabolic ovarian syndrome (PMOS).
The change reflects the recognition that the condition involves multiple endocrine and metabolic systems rather than simply the presence of ovarian cysts.
The former name was frequently misunderstood.
Despite the terminology, true pathological ovarian cysts are not necessary for diagnosis.
The condition can involve ovulatory dysfunction, androgen excess, and characteristic ovarian findings, together with broader metabolic and psychological health concerns.
The new name aims to improve scientific accuracy, clinical awareness, and patient understanding.
However, the change is being implemented gradually.
Many clinical guidelines and healthcare systems still use the term PCOS.
For this reason, both terms may appear in contemporary patient education.
A 2025 Nature Reviews Endocrinology article, Polycystic Ovary Syndrome as a Metabolic Disease, provides additional support for understanding this condition through its metabolic features.
The authors describe how insulin resistance, adipose tissue dysfunction, and other mechanisms contribute to heterogeneity among affected individuals.
The goal of this reframing is not to suggest that every woman with PCOS/PMOS has obesity.
Individuals across different body sizes can experience the condition.
Rather, it recognizes that reproductive and metabolic assessment are both important.
8. The Metabolic–Reproductive Feedback Loop in PCOS/PMOS
The relationship between insulin resistance and ovarian function can become self-reinforcing.
Insulin resistance may contribute to elevated circulating insulin.
Elevated insulin can interact with ovarian pathways involved in androgen production.
Insulin-related reductions in SHBG may increase biologically available androgens.
Androgen excess can influence adipose tissue distribution and metabolic regulation.
In some individuals, these processes may further aggravate insulin resistance.
The resulting feedback loop can contribute to persistent metabolic and reproductive symptoms.
However, not every individual demonstrates the same mechanism or severity.
Some women primarily experience ovulatory disturbances.
Others have more prominent metabolic abnormalities.
Still others experience substantial androgen-related symptoms.
This heterogeneity is one reason personalized assessment is so important.
A single laboratory marker or universal treatment program cannot adequately characterize every presentation.
9. Endometriosis and Metabolic Health: An Emerging Connection
Endometriosis involves the presence of tissue resembling the uterine lining outside the uterus.
It can produce pelvic pain, painful menstruation, and other symptoms, and may be associated with infertility.
Although endometriosis is commonly understood through reproductive and inflammatory mechanisms, researchers are also investigating its relationship with metabolism.
The 2026 Nature Metabolism review discusses evidence involving lipid metabolism, immune activity, and metabolic changes within endometriotic lesions.
Some studies have identified associations between endometriosis and cardiometabolic risk factors.
Other investigations suggest that altered cholesterol metabolism may influence cellular processes relevant to lesion development.
However, the causal relationships remain uncertain.
The evidence does not establish that endometriosis results from poor dietary choices or that correcting insulin resistance will reliably resolve lesions.
Nor does it establish that dietary interventions can replace established gynecological treatment.
The broader significance is that reproductive disorders may interact with metabolic processes in ways that deserve further investigation.
10. Energy Availability: Why Insufficient Fueling Can Disrupt Reproductive Function
Not all reproductive dysfunction is associated with excess energy storage or insulin resistance.
Insufficient energy availability can also influence reproductive regulation.
This is particularly relevant to women who exercise extensively, restrict dietary intake, or experience substantial changes in body weight.
When energy availability becomes insufficient, physiological adjustments may affect hypothalamic GnRH signaling.
This can contribute to changes in luteinizing hormone pulsatility and ovarian hormone production.
Functional hypothalamic amenorrhea is one example of a condition involving suppression of reproductive signaling in association with factors such as inadequate energy availability, psychological stress, or substantial physical demands.
However, absent menstrual periods have many possible causes.
Pregnancy, thyroid disease, hyperprolactinemia, PCOS/PMOS, and other conditions may need to be considered.
The clinical implication is that improving metabolic health does not always mean reducing energy intake.
For some individuals, the appropriate intervention may involve increasing nutritional intake, reducing excessive exercise demands, or improving recovery.
This is particularly important for athletes and physically active women.
11. Pregnancy: A Period of Major Metabolic Adaptation
Pregnancy introduces substantial changes in energy requirements and metabolic regulation.
Maternal physiology must support both the pregnant individual and the developing fetus.
As pregnancy progresses, insulin sensitivity normally changes.
Increased insulin resistance during later pregnancy helps redistribute nutrient availability.
This is a normal physiological adaptation.
However, gestational diabetes mellitus can develop when pancreatic insulin secretion is insufficient to compensate for the degree of pregnancy-related insulin resistance.
The 2026 review discusses gestational diabetes as a major example of the relationship between metabolic regulation and reproductive health.
It also examines hypertensive disorders of pregnancy, including preeclampsia.
These conditions involve complex interactions among vascular regulation, metabolic health, placental function, and other factors.
They require appropriate obstetric monitoring and medical management.
Importantly, pregnancy-related metabolic abnormalities can have implications beyond the immediate pregnancy.
A history of gestational diabetes is associated with elevated future risk of type 2 diabetes.
Pregnancy can therefore provide important information about long-term cardiometabolic health.
12. Nutrition Before and During Pregnancy
Nutritional requirements change before conception and throughout pregnancy.
Adequate energy and nutrient intake are essential for maternal health and fetal development.
Several nutrients deserve particular attention, including folate, iron, iodine, choline, calcium, and other nutrients according to individual circumstances.
However, nutritional needs depend on medical history, dietary patterns, and pregnancy stage.
The 2026 review discusses the possible influence of micronutrient imbalance and metabolic conditions on pregnancy outcomes.
Nevertheless, individual nutritional biomarkers do not independently predict every reproductive outcome.
A comprehensive approach considers dietary adequacy, relevant laboratory findings, medical history, and established preconception or prenatal guidance.
Nutritional deficiencies should be identified and addressed appropriately.
At the same time, unnecessary supplementation or restrictive dietary interventions should be avoided.
Women planning pregnancy or currently pregnant should coordinate relevant medical decisions with their obstetric and reproductive healthcare professionals.
13. Reproductive Aging: Why Menopause Changes Metabolic Health
Menopause represents a major transition in reproductive endocrine regulation.
It is characterized by the permanent cessation of menstrual periods associated with loss of ovarian follicular activity.
The menopausal transition involves changes in estradiol, progesterone, FSH, and other hormones.
These changes can influence several physiological systems.
The 2026 Nature Metabolism review discusses associations between reproductive aging and changes in insulin sensitivity, fat distribution, lipid metabolism, and cardiometabolic risk.
A complementary 2024 Nature Aging review, Exploring the Effects of Estrogen Deficiency and Aging on Organismal Homeostasis During Menopause, examines how estrogen signaling influences whole-body metabolic regulation.
The authors describe how changes in estrogen activity may interact with the effects of aging.
However, menopause does not affect every woman identically.
Changes in body composition, physical activity, sleep, genetics, and existing health conditions influence outcomes.
The distinction between the effects of menopause and chronological aging remains scientifically important.
14. Why Fat Distribution May Change After Menopause
Estrogen signaling contributes to the regulation of adipose tissue distribution.
Before menopause, women generally demonstrate a greater tendency toward subcutaneous fat storage.
Following menopause, changes in estrogen signaling may contribute to increased central adiposity.
These changes can influence metabolic risk.
However, fat redistribution is not inevitable to the same degree in every individual.
Physical activity, nutrition, genetics, sleep, and other circumstances remain relevant.
The practical implication is that metabolic health should be assessed across reproductive transitions.
Body weight alone may not capture meaningful changes in body composition or cardiometabolic risk.
Appropriate assessment can include blood pressure, glucose-related measurements, lipid profiles, and other established indicators according to individual risk.
15. FSH: More Than a Marker of Ovarian Aging?
Follicle-stimulating hormone is traditionally understood through its role in ovarian follicular development.
During menopause, circulating FSH concentrations generally increase as ovarian feedback changes.
However, researchers are investigating whether FSH also influences processes outside the reproductive system.
The 2026 review discusses experimental evidence involving FSH signaling in the liver, adipose tissue, and pancreas.
Some studies suggest that FSH may contribute to changes in cholesterol metabolism, fat distribution, and glucose regulation.
These findings are scientifically interesting.
However, several proposed mechanisms rely substantially on animal or laboratory research.
They do not establish that suppressing FSH is an appropriate routine strategy for preventing metabolic disease after menopause.
Likewise, circulating FSH concentrations should not be treated as a comprehensive measure of metabolic health.
The clinical implications require further research.
16. Nutrition: What Does the Evidence Actually Support?
Dietary strategies are frequently promoted for hormonal balance, fertility, and metabolic health.
These may include low-carbohydrate diets, ketogenic diets, Mediterranean dietary patterns, fasting protocols, and other approaches.
However, evidence quality varies substantially among interventions and outcomes.
The 2026 Nature Metabolism review discusses nutritional interventions for PCOS/PMOS and other reproductive conditions.
One important finding is that current evidence does not establish one universally superior dietary composition for women with PCOS/PMOS.
The 2023 International Evidence-Based Guideline similarly recommends healthy eating patterns tailored to individual preferences and goals.
The guideline emphasizes avoiding unnecessarily restrictive or nutritionally unbalanced diets.
This is particularly important because the individual's metabolic and reproductive characteristics matter.
Some women may benefit from strategies focused on improving glucose regulation.
Others may require attention to insufficient energy intake or nutritional deficiencies.
Still others may prioritize sustainable dietary habits that support long-term cardiovascular health.
The goal is not to prescribe one hormonal diet. It is to identify which nutritional changes are appropriate for the individual and supported by evidence.
17. Time-Restricted Eating and Ketogenic Diets: What Is Still Uncertain?
The 2026 review discusses emerging studies involving time-restricted eating and ketogenic diets among women with PCOS/PMOS.
Some investigations report improvements in body weight, insulin resistance, and androgen-related measurements.
However, several important questions remain.
For time-restricted eating, researchers must determine whether benefits arise from meal timing itself, changes in energy intake, or other behavioral factors.
Long-term effects on ovulation, pregnancy, and fertility remain incompletely established.
Ketogenic dietary interventions have also demonstrated improvements in selected metabolic outcomes in some studies.
However, evidence for clinically meaningful reproductive outcomes remains limited.
These approaches may also be unsuitable for certain individuals.
Pregnancy, disordered eating, insufficient energy availability, medication use, and other medical considerations can substantially influence their appropriateness.
Consequently, emerging nutritional interventions should not be presented as universally effective fertility treatments.
18. Physical Activity: Connecting Movement With Reproductive Health
Physical activity influences several processes relevant to metabolic and reproductive health.
Exercise can improve insulin sensitivity, cardiovascular fitness, muscular function, and body composition.
The 2026 review describes evidence that exercise interventions may improve selected metabolic and endocrine outcomes among women with PCOS/PMOS.
However, comparisons among exercise modalities remain limited by differences in study design, intervention intensity, duration, and participant characteristics.
The evidence does not establish that one exercise modality is universally superior for hormonal or reproductive outcomes.
Aerobic exercise and resistance training offer complementary benefits.
The most appropriate program depends on the individual's health status, goals, current capacity, and recovery needs.
Importantly, more exercise is not always better.
When training demands exceed available energy and recovery resources, reproductive function may become disrupted.
Effective exercise prescription therefore requires an appropriate balance between activity, fueling, and physiological adaptation.
19. GLP-1 Receptor Agonists and Metabolic–Reproductive Research
GLP-1 receptor agonists are medications that influence glucose regulation, appetite, and other metabolic processes.
They have become increasingly important in diabetes and obesity treatment.
Researchers are investigating whether their metabolic effects may also influence reproductive outcomes in selected women.
The 2026 review discusses emerging evidence involving PCOS/PMOS and GLP-1 receptor agonists.
Some studies demonstrate improvements in weight and metabolic parameters.
However, important uncertainties remain regarding effects on ovulation, fertility, and other reproductive outcomes independent of weight loss.
Medication safety and pregnancy planning are particularly important considerations.
These medications should not be used as general fertility treatments without established indications and appropriate medical oversight.
Their potential reproductive applications remain an evolving area of research.
20. Metformin and Metabolic–Reproductive Care
Metformin is widely used in the management of type 2 diabetes and selected metabolic conditions.
It reduces hepatic glucose production and influences aspects of insulin-related metabolism.
The 2023 international PCOS guideline recognizes metformin as an option for specific metabolic features of PCOS/PMOS.
The 2026 review discusses evidence involving metabolic outcomes and possible reproductive benefits.
However, treatment selection depends on clinical circumstances.
Metformin does not serve as a universal replacement for established fertility treatments, and its use during pregnancy requires individualized medical decision-making.
These findings demonstrate that metabolism-targeted treatment can have a meaningful role in reproductive healthcare.
They do not establish that every reproductive disorder should be treated by lowering insulin or pursuing weight loss.
21. Precision Women's Health: From Isolated Hormones to Interacting Systems
The emerging science of metabolic–reproductive communication creates an opportunity for more individualized healthcare.
Rather than considering menstrual symptoms, glucose regulation, body composition, and reproductive life stage as unrelated concerns, clinicians can investigate whether meaningful relationships exist.
However, comprehensive assessment should not be confused with ordering every available laboratory test.
The most useful assessment begins with the clinical question.
For example, irregular menstrual cycles may require evaluation of pregnancy status, thyroid function, prolactin, ovarian conditions, and other relevant factors.
Signs of androgen excess may warrant appropriate endocrine investigation.
Women with known PCOS/PMOS may benefit from established cardiometabolic risk assessment.
Individuals experiencing fatigue or menstrual dysfunction in the setting of high training loads may require evaluation of nutritional adequacy and energy availability.
The objective is to select validated measurements that can guide meaningful care.
Emerging research on kisspeptin, adipokines, hepatokines, and other signaling molecules may eventually expand these capabilities.
However, most are not yet established routine biomarkers for directing reproductive treatment.
22. The Importance of a Lifespan Perspective
Women's reproductive health changes substantially throughout life.
Puberty involves maturation of the HPO axis.
The reproductive years involve recurring hormonal changes and potential pregnancy.
Pregnancy requires major metabolic adaptation.
Perimenopause and menopause introduce additional endocrine and metabolic transitions.
These stages create different physiological demands.
Consequently, recommendations appropriate for one life stage may be inappropriate for another.
A young athlete experiencing insufficient energy availability may require improved fueling.
A woman with PCOS/PMOS and insulin resistance may benefit from targeted cardiometabolic management.
Someone preparing for pregnancy may need preconception nutritional assessment and appropriate medical care.
A woman transitioning through menopause may benefit from attention to cardiovascular risk, physical fitness, bone health, and changing symptoms.
These differences reinforce the importance of personalized healthcare across the lifespan.
23. How This Research Informs Women's Health
We recognize that women's health cannot be adequately understood through reproductive hormones alone.
Nutrition, movement, sleep, stress, metabolic regulation, and environmental conditions all contribute to the broader physiological context in which reproductive health occurs.
The 2026 Nature Metabolism review provides an important scientific foundation for understanding these relationships.
Its central message is that metabolic and reproductive systems communicate continuously.
Our approach emphasizes comprehensive wellness education, individualized lifestyle strategies, and attention to clinically relevant physical-health concerns.
Within our HER women's health philosophy, this may involve exploring nutritional adequacy, metabolic health, physical activity, sleep, stress-related behaviors, and reproductive life-stage considerations.
When appropriate, relevant clinical assessments may help identify concerns requiring additional investigation or referral.
We also recognize that reproductive disorders require appropriate professional evaluation.
Conditions such as infertility, endometriosis, gestational diabetes, and ovarian or pituitary disorders may require specialized gynecological, endocrinological, reproductive, or obstetric care.
Our wellness services are not substitutes for these treatments.
Nor do we claim that optimizing one metabolic marker necessarily restores ovulation, resolves endometriosis, or prevents pregnancy complications.
Instead, we emphasize evidence-informed strategies that support relevant aspects of metabolic and general health alongside appropriate medical care.
The objective is to understand the individual woman's needs rather than assume every reproductive concern has the same underlying explanation.
Conclusion: Women's Reproductive Health Is a Whole-Body Process
The relationship between metabolism and reproduction is far more complex than traditional organ-based explanations sometimes suggest.
The hypothalamus and pituitary coordinate ovarian activity.
Adipose tissue communicates information about energy availability.
The pancreas influences glucose regulation and interacts with reproductive hormone signaling.
The liver participates in hormone transport and metabolism.
Skeletal muscle and physical activity influence metabolic adaptation.
These systems do not function independently.
They participate in a dynamic network that changes throughout the lifespan.
The 2026 Nature Metabolism review provides a comprehensive framework for understanding these interactions.
Its findings help explain why metabolic dysfunction can contribute to certain reproductive disorders and why reproductive transitions can influence metabolic health.
However, the research also reinforces the importance of clinical nuance.
Not all reproductive conditions arise from insulin resistance.
Not every woman benefits from weight loss.
And no single dietary strategy, exercise program, supplement, or metabolic measurement can adequately address every form of reproductive dysfunction.
The future of personalized women's healthcare is not about treating hormones in isolation. It is about understanding the metabolic, neurological, endocrine, behavioral, and environmental systems through which reproductive health emerges.
We believe this comprehensive perspective helps women make more informed decisions about their health while supporting appropriate, individualized care across every stage of life.
Research References
Liu X, Yang L, Jiang J, Chang H-M, Mu L. Metabolic homeostasis and women's reproductive health. Nature Metabolism. Published October 15, 2026. https://doi.org/10.1038/s42255-026-01646-1
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026;407:2329–2339. https://doi.org/10.1016/S0140-6736(26)00717-8
Kordowitzki P, Teede H. Polyendocrine metabolic ovarian syndrome—a new name for an old problem. Nature Metabolism. 2026;8:1443–1445. https://doi.org/10.1038/s42255-026-01552-6
Helvaci N, Yildiz BO. Polycystic ovary syndrome as a metabolic disease. Nature Reviews Endocrinology. 2025;21:230–244. https://doi.org/10.1038/s41574-024-01057-w
Camon C, Garratt M, Correa SM. Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause. Nature Aging. 2024;4:1731–1744. https://doi.org/10.1038/s43587-024-00767-0
Moran LJ. Advances in cardiometabolic outcomes in polycystic ovary syndrome. Nature Reviews Endocrinology. 2025;21:67–68. https://doi.org/10.1038/s41574-024-01072-x
Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction. 2023;38:1655–1679. https://doi.org/10.1093/humrep/dead156